print verstuur

Technology Transfer

Technology Transfer

One of the spearheads of NVI's policy is to contribute to the availability of vaccine world-wide. The NVI is willing to offer his facilities and knowledge to provide other institutes in middle- and lower income countries, the possibility to build, improve and/or expand their own production facility. NVI realizes this by technology transfer to competent vaccine producers in lower- and middle income countries. For example, NVI has recently developed a production process for Hib conjugate vaccine that has been successfully transferred to vaccine producers in India and Indonesia.

Also, the NVI works together in vaccine development projects with governmental institutions with vaccine development capabilities in Europe. Such as the Staten Serum Institute (Denmark), The Health Protection Agency (UK), KTL (Finland), NCE (Hungary) and Cantacuzino Imstitute (Romania).

And last but certainly not least, the NVI functions as training centre within the WHO Global Training Network for Vaccine Quality (GTN-VQ) and the WHO Initiative for Vaccine Research (IVR).

WHO, influenza and polio...

Under a Memorandum of Understanding between WHO and NVI, signed for an initial five-year period, NVI is establishing since early 2008 in-house an egg-based pilot seasonal influenza vaccine production process suitable for up scaling, training and technology transfer to manufacturers in lower- and middle income countries. This project is called the International Technology Platform for Influenza Vaccines (ITPIV). Read more here or use this link to navigate to the website.

Another WHO-project is Sabin-IPV. In this project, The NVI will establish, test and document a production process for Sabin-inactivated polio vaccine (IPV) based on the current Salk-IPV production technology. Read more here or use this link to the website.